February 11, 2013

HVP III Portfolio Company Clinipace Worldwide makes Top 40 on FORBES’ Most Promising Companies List

February 6, 2013 – Clinipace Worldwide, a digital clinical research organization (dCRO), announced today announced that the company has been listed at No. 36 on FORBES annual ranking of America’s Most Promising Companies — a list of 100 privately held, high-growth companies with bright futures. Clinipace is a portfolio company of Hatteras Venture Partners III. This prestigious list is based on growth (both in sales and hiring), quality of management team and investors, margins, market size and key partnerships. Clinipace has closed four global acquisitions over the past three years. Most recently, Clinipace acquired Paragon Biomedical, expanding its therapeutic expertise, site management capabilities, and clinical operations.  In addition, the company extended its global footprint with the addition of offices in Irvine, California, High Wycombe, United Kingdom, and Trivandrum, India.  Clinipace now employs over 450 individuals globally. “It is an honor to be named to FORBES’ ranking of America’s Most Promising Companies,” said Jeff Williams, CEO, Clinipace Worldwide. “We owe this achievement to the dedication and expertise of our employees who work tirelessly to deliver a new service delivery model with which we are changing and improving the way clinical trials are run through a technology-enabled platform.” About FORBES Most Promising Companies List One metric never says it all. For the Most Promising list, FORBES strove for a holistic gauge of young, privately-held companies, trying to pin down their trajectories by looking at a slew of variables. Over the course of six months, FORBES reviewed thousands of applications. The final assessment is based on growth (both in sales and hiring), quality of management team and investors, margins, market size and key partnerships. FORBES turned to CB Insights, a Manhattan-based data research firm that specializes in assessing private companies, to refine the search. Their MOSAIC software scans 45,000 sources to measure a company’s health. A new distribution deal, for example, marks a positive signal, while the loss of an executive is a negative. MOSAIC gathers those myriad signals into a final score that FORBES uses as an initial guide in producing the list. After verifying sales numbers, speaking with each company and debating their merits and blemishes, FORBES produces a final ranking. About Clinipace Worldwide As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms.  Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program.  We have managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies).  Clinipace Worldwide is headquartered in Research Triangle Park, North Carolina with offices in Irvine (CA), Boulder (CO), Overland Park (KS), Zurich (CH), Munich (DE), High Wycombe (UK), Tel-Aviv (IL), Sao Paulo (BR), Buenos Aires (AR), Trivandrum Kerala (IN) and New Delhi (IN).  For more information, visit our website at clinipace.com.